CPMV — what changed in the latest 10-Q
A section-by-section comparison of CPMV's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-20
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +10 | −9 | ~6 | 11 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 1 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
Research and development expenses of approximately $16,000 for the three months ended June 30, 2026 and 2025, respectively, are primarily related to salaries and related costs for personnel in research and development functions.
General and administrative expenses of approximately $141,000 for the three months ended June 30, 2026 consist principally of salaries and related costs for personnel and consultants in executive and administrative functions of approximately $117,000, accounting and filing fees of approximately $17,…
Interest expense of approximately $21,000 and $21,000 for the three months ended June 30, 2026 and 2025 , respectively, represents interest expense on convertible notes and loan payables.
Research and development expenses of approximately $31,000 for the six months ended June 30, 2026 are primarily related to salaries and related costs for personnel in research and development functions. The decrease in research and development expenses of approximately $1,000 for the six months ende…
General and administrative expenses of approximately $280,000 for the six months ended June 30, 2026 consist principally of salaries and related costs for personnel and consultants in executive and administrative functions of approximately $218,000, accounting and filing fees of approximately $44,00…
Text removed vs the prior filing · source: 10-Q · 2026-05-20
Research and development expenses of approximately $16,000 for the three months ended March 31, 2026 are primarily related to salaries and related costs for personnel in research and development functions. We believe our research and development expenses will increase significantly over time if we a…
General and administrative expenses of approximately $139,000 for the three months ended March 31, 2026 consist principally of salaries and related costs for personnel and consultants in executive and administrative functions of approximately $101,000, accounting and filing fees of approximately $28…
On July 1, 2024, we entered into a Master Services Agreement with Oncotelic whereby we perform advisory and related services in connection with studies and projects. For the three months ended March 31, 2025, we earned $14,000 for advisory and related services which is recorded in other income in th…
Interest Expense and Accretion to Redemption Value on Convertible Notes
Interest expense of approximately $21,000 and $21,000 for the three months ended March 31, 2026 and 2025, respectively, represents interest expense on convertible notes and loan payables.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice